Inhibikase IKT (Parkinson's) MK $33Mio -> 5Mrd+ bis Ende 2023(?!) (Seite 3)

[soulist]

mikedar
11:50 AM
$IKT
IKT has some qualified Managers

Roger Rush, Ph.D.
Preclinical Project Management

From March 2012 to December 2014, he was Vice President, Preclinical Development for Idenix Pharmaceuticals, Inc., a wholly owned subsidiary of Merck & Company, Inc., where he managed the DMPK, toxicology, and discovery research that led to the identification of lead molecules to treat Hepatitis C virus.
Idenix Pharmaceuticals, Inc., bought out by Merck & Company, Inc
The transaction, valued the purchase of Idenix at approximately $3.85 billion.

$3.85 billion/30 mill IKT share count current is 128$ a share... just saying... a little potential????
https://stocktwits.com/mikedar/message/450185809

[soulist]

[soulist]

Ein eher kritischer Begleiter auf Stocktwits, aber hier gehe ich voll mit:

soufre88 04:19 PM
Dr. Werner is a brilliant, eminently qualified scientist, however I would like to see him bring in some Industry/Pharma help.
I know he has said no to a partnership before phase 2, but I believe he should reconsider that. If he can get a deal like Novartis gave UCB ($150m upfront, $1.5b biobucks) a few months ago for their small molecule a-syn inhibitor(w/ only phase 1b data in hand) he should consider it to derisk his exposure.
https://stocktwits.com/soufre88/message/436816617

"Novartis has seen enough promise in the early data to write UCB a check. In return for a $150 million upfront payment, and the promise of much more down the line, Novartis has secured the right to co-develop and co-commercialize UCB0599. UCB will take the lead commercially in Europe and Japan, leaving Novartis to handle the U.S. and all other territories."
https://www.fiercebiotech.com/biotech/alpha-challenger-novar…

[soulist]

Abl Kinase Inhibition: Disease Modifying Strategy For Parkinson’s Disease

[soulist]

Antwort auf Beitrag Nr.: 70.614.961 von soulist am 24.01.22 11:02:17

[soulist]

Inhibikase Therapeutics
@inhibikase
Inhibikase's Prodrug technology is a technology platform that enables greater control over non-hematological side effects common to kinase inhibitor therapies, such as nausea or diarrhea, and may improve drug delivery into the target tissue. https://bit.ly/2ZLven4 $IKT

Original (Englisch) übersetzt
Die Prodrug-Technologie von Inhibikase ist eine Technologieplattform, die eine bessere Kontrolle über nicht-hämatologische Nebenwirkungen ermöglicht, die bei Therapien mit Kinase-Inhibitoren üblich sind, wie Übelkeit oder Durchfall und die Arzneimittelabgabe in das Zielgewebe verbessern kann.
https://www.inhibikase.com/about

[soulist]

Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders (z.b. Alzeimer)

1Q 2022 BUSINESS PRESENTATION

https://d1io3yog0oux5.cloudfront.net/_5ce61bdbf47e2aa9222f22…


$33 Mio Marktkapitalisierung
$44 Mio Cash (genug um uns durchP2 zu bringen und praktisch schuldenfrei)


Common Shares Outstanding 25,177,051 (January 4, 2022)

Options (WAEP: $2.47)3,580,952

Warrants (WAEP: $5.21) 1,561,913

Fully Diluted Shares Outstanding 30,319,916


Insider Ownership Percentage: 55.80%

Insider Buying (Last 12 Months): $46,470.33 (zu $2 30% über damaligen Aktienkurs)

Insider Selling (Last 12 Months): $0.00

insidertrades.com/inhibikase-therapeutics-inc-stock/

34 funds or institutions reporting positions in Inhibikase Therapeutics Inc. This represents an increase of 8 owner(s) and 30.77 percent in the last three months.

Total shares owned by institutions increased in the last three months to 4,169,757 shares. fintel.io/news/...bikase-therapeutics-inc-0.37647418272841804

Bei Insider ownership von 55,8%, sind also lediglich 6,88 Mio Shares im free float.

"Certainly doesn’t take many shares to push this puppy up can’t imagine when positive news actually is released what it would do."


Dr. Milton Werner zum Thema ab 1:24:41
"At what shareprice would you sell?"

Er macht kein Geheimnis draus, dass nach erfolgreicher Phase 2 die ganze Geschichte verkauft wird, um das Medikament auf schnellsten Wege zu den Patienten zu bringen.

"...finding reasons to sell after successful P2 results. First it was the joke in a previous interview about how he would be fired for not taking a buyout offer. Now it’s a strategy: fastest route to patient. Everything’s set for phase 2 and the value is unrealized so push thru. He’s a one man show and would be unable to proceed efficiently by himself. If an EUA was granted after successful P2 big pharma could have that on the market in no time..."

Dr. Milton Werner Part I “...safety properties and selectivity that has never been seen in our view...”

Dr. Miilton Werner Part II “...the value of that drug (transformative drug IKT 148009) in our view is ASTRONOMICAL...“

Dr. Milton Werner Part III "...We’ve done a full commercial opportunity assessment, to us that means this is a product (transformative drug IKT 148009) that could earn between 9 and 13B a year at a 50% market share.”

$10 Mrd pro Jahr bei 50% Marktanteil - Dr.Werner spricht selbst euphorisch vom "holy grail"

A $5B sale of the company gives a share price of $150 at 30M shares fully diluted.
150 Dollar klingen weit entfernt bei einem Schlusskurs am Freitag von $1.32 - schaun wir mal, wie's ultimo 2023 aussieht.
Ist nicht lang hin...